P/E ratio for Exact Sciences (EXAS)
P/E ratio as of September 2023 (TTM): -27.3
According to Exact Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -27.3374. At the end of 2021 the company had a P/E ratio of -22.5.
P/E ratio history for Exact Sciences from 2002 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -22.5 | -5.94% |
| 2020 | -23.9 | -81.64% |
| 2019 | -130 | 197.25% |
| 2018 | -43.8 | -16.6% |
| 2017 | -52.5 | 548.88% |
| 2016 | -8.10 | 49.13% |
| 2015 | -5.43 | -75.46% |
| 2014 | -22.1 | 29.95% |
| 2013 | -17.0 | 41.51% |
| 2012 | -12.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 18.5 | -167.56% | 🇫🇷 France |
 Veracyte VCYT | -56.5 | 106.49% | 🇺🇸 USA |
 Antares Pharma ATRS | 16.4 | -160.14% | 🇺🇸 USA |
 Myriad Genetics MYGN | -5.26 | -80.76% | 🇺🇸 USA |
 Biocept
BIOC | -0.7519 | -97.25% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.